Core Viewpoint - Abbott's financial performance for 2025 shows overall revenue and earnings growth, with significant contributions from the medical devices segment, while nutrition and diagnostics face challenges [1][3][22]. Overall Financial Performance - In Q4 2025, Abbott reported total sales of approximately $11.46 billion, with a net profit of $1.78 billion, leading to a diluted EPS of $1.01 and an adjusted EPS of $1.50, slightly above market expectations [4][5]. - For the full year 2025, total sales reached about $44.33 billion, with a diluted EPS of $3.72 and an adjusted EPS of $5.15, achieving double-digit growth [4][21]. Business Segment Breakdown Medical Devices - The medical devices segment continues to be the standout performer, with Q4 sales of $5.68 billion, reflecting a 12.3% year-over-year growth [8][9]. - Growth in this segment is driven by products related to cardiac rhythm management, electrophysiology, and chronic disease management solutions [7][8]. Nutrition - The nutrition segment is currently under pressure, with Q4 sales of $1.94 billion, down 8.9% year-over-year [10][12]. - The decline is attributed to ongoing adjustments in pricing strategies and product mix, which are expected to persist [10][22]. Diagnostics - The diagnostics segment reported Q4 sales of $2.46 billion, a decrease of 2.5% compared to the previous year, primarily due to declining demand for COVID-19 testing [13][15]. - The segment's performance reflects a broader trend of reduced testing needs impacting overall revenue [13][22]. Established Pharmaceuticals - The established pharmaceuticals segment generated Q4 sales of $1.38 billion, maintaining stable growth, particularly in international markets, with a 9.0% increase year-over-year [16][18]. Key Operational Developments - Abbott has received regulatory approval for its first pulse field ablation system for atrial fibrillation patients and has made progress with several cardiovascular and electrophysiology products in Europe [20]. - The company plans to acquire Exact Sciences for approximately $21 billion to expand its oncology screening and diagnostic capabilities [20][21]. 2026 Financial Outlook - For 2026, Abbott's management anticipates accelerated growth driven by new product launches and ongoing business structure optimization [21][22].